Akebia Therapeutics is a fully integrated renal biopharmaceutical company dedicated to advancing new hope for people with kidney disease. With a strong focus on research and development, Akebia is committed to making a difference by challenging the status quo. They offer a range of innovative products and services that address the complications of kidney disease.

Akebia has a commercially available medicine that is approved for use in 34 countries called VAFSEO® (vadadustat). Additionally, they have a late stage oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) known as vadadustat, which is currently in global Phase 3 clinical development. Akebia's team of experts works tirelessly to protect the kidneys and innovate for better lives.

Their products, including vadadustat, are based on Nobel Prize-winning science, and they are a trusted leader in the renal community. While vadadustat hasn't yet been approved by the U. S.

Food & Drug Administration, Akebia continues to push the boundaries of renal treatment, offering hope to millions affected by chronic kidney disease. Join Akebia Therapeutics in their mission to make a positive impact in the field of kidney disease and contribute to the advancement of innovative treatments for patients and their families